Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City. Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for 2022. There will also be a demonstration of the Simcyp™ Simulator.
The live video webcast of the event, along with a slide presentation, will be available on Certara's Investor Relations website at https://ir.certara.com/events/event-details/certara-investor-day. A replay of the event will be archived on the Investor Relations website for 2 weeks following the event.
About Certara
Certara accelerates medicines using proprietary biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Certara Contact
Jieun W. Choe
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contacts:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.02 |
Daily Change: | 0.05 0.46 |
Daily Volume: | 1,148,777 |
Market Cap: | US$1.770B |
August 06, 2025 August 04, 2025 July 31, 2025 May 05, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load